

3SBio (1530 HK)

ASCO 2026 takeaways: encouraging first mPFS readout for 707 in 1L PD-L1+ NSCLC

ASCO 2026 disclosed two abstracts for 707/ PF'4404 in 1L PD-L1+ NSCLC mono and 1L EC in combination with chemo. On a cross-trial basis, 707 demonstrated competitive mPFS versus ivonescimab in 1L NSCLC, with particular strength in the NSQ subgroup. 707 also showed encouraging ORRs in 1L EC, especially in pMMR patients. We continue to expect partner Pfizer's global trial execution and additional clinical readouts to be the main drivers of stock price upside for 3SBio.

- First mPFS readout solidified 707 as a competitive candidate in 1L PD-L1+ NSCLC.** In the China Ph2 study in 1L PD-L1+ NSCLC, 707 mono (10 mg/kg Q3W) achieved mPFS of 12.4 months, slightly ahead of ivonescimab's 11.14 months reported in [HARMONI-2](#) on a cross-trial basis. By subgroup, mPFS was 12.4 months in both PD-L1 high and NSQ patients (vs. ~11 months for ivonescimab). The PFS benefits of 707 and ivonescimab in PD-L1 low subgroup are largely at the same level (see Figure 1). In our view, the data support 707 as a highly competitive candidate in PD-(L)1/VEGF class. On safety, Gr3+ TRAEs rate was 42.2% across 83 patients in all dose subgroups, with Gr3+ irAEs and VEGF-related AEs were 8.4% and 18.1%, respectively. We note that this safety profile included higher-dose subgroups, including 20 mg/kg and 30 mg/kg Q3W, limiting direct cross-trial comparison. In the 10 mg cohort previously presented at ASCO 2025, Gr3+ TRAEs rate was 23.5%, versus 29.4% for ivonescimab in [HARMONI-2](#), suggesting a favorable safety profile at the intended dose.
- Encouraging preliminary 1L EC data.** The preliminary data for 707 + chemo in 1L EC were encouraging, especially in pMMR patients, who account for ~70% of EC and typically derive less benefit from immunotherapy. In pMMR EC, the 5mg and 10mg subgroups of 707 achieved cORRs of 83.3% and 81.8%, respectively, versus 72.3% for the current SOC of pembrolizumab + chemo on a cross-trial basis. Gr3+ TRAEs rate was 68.8% across 32 patients in both dose subgroups which was broadly manageable. Notably, Pfizer has already registered a global Ph3 study in 1L pMMR EC.
- Pfizer's strong clinical execution and further readouts should continue to be a key driver for 3Sbio.** Pfizer has registered eleven global studies for 707, including three global Ph3 studies across four 1L indications. Notably, Pfizer also plans to initiate a global Ph3 trial for 707+PADCEV (Nectin-4 ADC) in 1L UC in 2026E. Looking ahead, we expect additional China Ph2 readouts of 707+chemo in 1L NSCLC and mCRC in 2H26E, which could serve as near-term catalysts.
- Maintain BUY.** We view the ASCO 2026 data for 707 as encouraging and reiterate our positive view on its global potential. We maintain our target price unchanged at HK\$34.87 based on a 10-year DCF model (WACC: 10.11%, terminal growth rate: 2.0%).

Earnings Summary

(YE 31 Dec)	FY24A	FY25A	FY26E	FY27E	FY28E
Revenue (RMB mn)	9,108	17,696	9,170	9,168	10,090
YoY growth (%)	16.5	94.3	(48.2)	(0.0)	10.1
Net profit (RMB mn)	2,090	8,482	1,898	1,616	1,815
5 YoY growth (%)	34.9	305.8	(77.6)	(14.8)	12.3
EPS (Reported) (RMB)	0.86	3.51	0.75	0.64	0.72
P/E (x)	19.3	4.8	22.3	26.2	23.3
Net gearing (%)	(13.1)	(51.1)	(53.3)	(54.3)	(55.4)

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price **HK\$34.87**
 Up/Downside **81.4%**
 Current Price **HK\$19.23**

China Healthcare

Jill WU, CFA
 (852) 3900 0842
 jillwu@cmbi.com.hk

Cathy WANG
 (852) 3916 1729
 cathywang@cmbi.com.hk

Stock Data

Mkt Cap (HK\$ mn)	48,805.8
Avg 3 mths t/o (HK\$ mn)	701.8
52w High/Low (HK\$)	35.90/18.62
Total Issued Shares (mn)	2538.0

Source: FactSet

Shareholding Structure

TMF (Cayman) Ltd.	22.8%
Decade Sunshine	19.6%


Source: HKEX

Share Performance

	Absolute	Relative
1-mth	-15.5%	-14.3%
3-mth	-14.7%	-10.8%
6-mth	-36.8%	-36.1%

Source: FactSet

12-mth Price Performance



Source: FactSet

Figure 1: Clinical data comparison of PD-(L)1/VEGF bispecific antibodies in 1L PD-L1+ NSCLC

	707	ivonescimab		BNT327 (PD-L1/VEGF)
Company	3Sbio/ Pfizer	Akeso/ Summit		BioNTech/ BMS
Phase	Ph II	Ph III		Ph I/II
Trial name	NCT06361927	NCT05499390 (HARMONI-2)		NCT05918445
N	83 (all dosage subgroups)	398		30 (NSQ: n=17 SQ: n=13)
dosing	10 mg/kg Q3W (n=34)	Experimental: 20 mg/kg Q3W ivonescimab (n=198)	Control: Pembrolizumab (n=200)	20 mg/kg Q2W
Median follow-up	15.2 mo	8.67 mo		NSQ: 16.0 mo SQ: 8.8 mo
mPFS subgroup	12.4 mo PD-L1 HIGH: 12.4 mo (n=13) PD-L1 LOW: 9.6 mo (n=21) ; NSQ: 12.4 mo (n=22) SQ: 8.9 mo (n=12)	11.14 mo, PFS HR=0.51 (P<0.0001) PD-L1 HIGH: ~11 mo (n=13) PD-L1 LOW: ~9 mo (n=21) ; NSQ: ~11.1 mo (n=22) SQ: ~9.7 mo (n=12)	5.82 mo	NSQ: 13.6 mo
ORR subgroup	cORR=67.6% PD-L1 HIGH: 76.9% (n=13) PD-L1 LOW: 61.9% (n=21) ; NSQ: 63.6% (n=22) SQ: 75.0% (n=12)	50.0%	38.5%	uORR=53.3% NSQ: uORR=47.1% (PD-L1 HIGH: uORR=50.0% (n = 8) PD-L1 LOW: uORR=44.4% (n = 9) ; SQ: uORR=61.5% (PD-L1 HIGH: uORR=71.4% (n = 7) PD-L1 LOW: uORR=50.0% (n = 6)
TRAE	97.1%	89.8%	81.9%	-
TRAE (Gr3+)	23.5% (ASCO 2026公布更新数据, 所有剂量组 83例患者中, Gr3+ TRAE 42.2%, 其中ir- related Gr3+ AE 8.4%, VEGF-related Gr3+ AE 18.1%)	29.4%	15.6%	40.0%
Reference	Link	Link		Link

Source: 3Sbio, ASCO 2026, Akeso, BioNTech, CMBIGM

Figure 2: Clinical data comparison in 1L advanced/ recurrent EC

	707 (PD-1/VEGF)	Pembrolizumab (PD-1)*		HB0025 (PD-L1/VEGF)
Company	3Sbio/ Pfizer	MSD		BioNTech/ BMS
Dosing group	707 with chemo	Pembrolizumab with chemo		华奥泰
Phase	Ph II	Ph III		Ph II
Trial name	NCT06522828	NCT03914612		NCT06758557
N	32 (pMMR: n=26, dMMR: n=6)	810 (pMMR: n=588, dMMR: n=222)		39
dosing	707 5mg/kg Q3W+paclitaxel + carboplatin: n=14 (pMMR n=12, dMMR n=2) 707 10 mg/kg Q3W+paclitaxel + carboplatin: n=15 (pMMR n=11, dMMR n=4)	Experimental: Pembrolizumab Q3W with paclitaxel + carboplatin n=404 (pMMR cohort: n=294 dMMR cohort: n=110)	Control: Placebo+paclitaxel + carboplatin n=406 (pMMR cohort: n=294 dMMR cohort: n=112)	HB0025 20mg/kg Q3W+paclitaxel + carboplatin
Median follow-up	-	Interim analysis: MMR cohort: 10.0 mo; dMMR cohort: 14.4 mo Ad Hoc analysis: MMR cohort: 20.8 mo; dMMR cohort: 22.5 mo		3.3 mo
mPFS subgroup	-	pMMR cohort: 19.5 mo (HR=0.64) dMMR cohort: NR (HR=0.45)	pMMR cohort: 11.0 mo dMMR cohort: 14.1 mo	-
ORR subgroup	5mg/kg Q3W: cORR=85.7% (5mg pMMR: cORR=83.3%, dMMR: cORR=100%) 10mg/kg Q3W: cORR=80.0% (10mg pMMR: cORR=81.8% uORR=90.9%, dMMR: cORR=75.0% uORR=100%)	pMMR cohort: ORR=72.3% dMMR cohort: ORR=82.1%	pMMR cohort: ORR=59.0% dMMR cohort: ORR=71.6%	ORR=83.9% (pMMR cohort: ORR=84.0%) dMMR cohort: ORR=100%)
TRAE	93.8%	96.9%	96.1%	-
TRAE (Gr3+)	68.8% (TRAE led to discontinuation in 2 pts (6.3%) , irAE: 18.8%, VEGF-related AE: 40.6%)	49.9%	34.0%	46.2% (No TRAE led to treatment discontinuation or death, irAE: 5.1%)
Reference	Link	Link		Link

Source: 3Sbio, ASCO 2026, Pharmcube, CMBIGM

* mPFS results were based on interim analysis assessed by BICR, while ORRs and safety profiles were based on Ad Hoc analysis assessed by investigators.

Figure 3: Registered global clinical trials of 707

Clinical stage ((Estimated)Study start)	Primary Completion (Estimated)	Indication	Enrollment (Estimated)	Regimen	Primary endpoints	ClinicalTrials. gov ID
III 期 (2026.1.6)	2029.02.27	联合化疗 1L NSCLC (Part 1: sq, Part 2: nsq) (Symbiotic-Lung-01)	1500 (700 for sq, 800 for nsq)	PF'4404 (10mg/kg Q3W) + Chemo vs Keytruda + Chemo	Dual Primary endpoints: PFS, OS	NCT07222566
III 期 (2025.12.11)	2030.03.29	联合化疗 1L mCRC (Non- MSI-H 或 pMMR) (Symbiotic-GI-03)	800	PF'4404 (10mg/kg Q2W) + Chemo vs BEVACIZUMAB + Chemo	Dual Primary endpoints: PFS, OS	NCT07222800
III 期 (2026.10.9)	2029.6.1	联合化疗 1L pMMR EC (Symbiotic-GYN-18)	600	PF'4404 + Chemo vs Keytruda + Chemo	Primary endpoints: PFS	NCT07578649
II/III 期 (2025.12.9)	2030.06.14	联合化疗 1L ES-SCLC (Symbiotic-Lung-04)	Ph2 (40), Ph3 (500)	PF'4404 + Chemo vs Atezolizumab + Chemo	Primary endpoints of Ph3: OS	NCT07226999
II/III 期 (2026.3.2)	2032.07.22	联合化疗 1L 胃癌、胃食管交 界处癌或食管腺癌	840	Ph3: PF'4404 + Chemo vs Nivolumab + Chemo	Ph3 Dual Primary endpoints: PFS, OS	NCT07392892
II 期 (2026.4.1)	2028.8.4	1) 联合化疗用于 II 期或 IIIA/B 期 NSCLC 的新辅助治 疗, 2) 已接受过新辅助免疫 化疗并完成手术、但术后病 理分析显示未达到 pCR 的 II 期或 IIIA/B 期 NSCLC 成年患 者, 3) 单药用于不可手术的 II 期或 IIIA/B 期 NSCLC 成年 患者 (Symbiotic-Lung-10)	120	PF'4404/ PF'4404+ Chemo	Primary endpoints: AEs, pCR rate	NCT07489066
II 期 (2026.5.15)	2028.3.19	联合化疗 1L 治疗 T-SCLC (Symbiotic-Lung-14)	40	PF'4404 + Chemo	Primary endpoints: ORR, AEs	NCT07476287
Ib/II 期 (2026.2.10)	2027.11.02	单药或联合 2 种其他药物 1L 治疗局部晚期或转移性肾细 胞癌 (Ia/mRCC) (Symbiotic-GU-08)	224	Monotherapy or + other 2 drugs	Primary endpoints: ORR、 AEs&SAEs、 DLT	NCT07227415
Ib/II 期 (2026.1.30)	2029.03.08	联合其他药物治疗 NSCLC (包括联合 SV(IB6 ADC) 1L 治疗 NSCLC) (Symbiotic-Lung-20)	162	Part A: + SV Part B: + other anticancer agent	Primary endpoints: ORR、 AEs&SAEs、 DLT	NCT07227298
Ib/II 期 (2025.12.1)	2027.10.18	单药或联合伊匹木单抗治疗 局部晚期或转移性肝细胞癌 (Ia/mHCC) (Symbiotic-GI-13)	138	Monotherapy or + ipilimumab	Primary endpoints: ORR、 AEs&SAEs、 DLT、 Recommend ed dose of PF'4404 in combination with ipilimumab	NCT07227012
Ib/II 期 (2026.2.27)	2027.12.06	单药治疗既往接受过治疗的 LA/mUC; 联合 PADCEV 1L LA/mUC (Symbiotic-GU-06)	132	Monotherapy or + PADCEV	Primary endpoints: ORR、 AEs&SAEs、 DLT	NCT07421700

Source: ClinicalTrial.gov, CMBIGM estimates

Figure 4: Risk-adjusted DCF valuation

DCF Valuation (in RMB mn)	2026E	2027E	2028E	2029E	2030E	2031E	2032E	2033E	2034E	2035E
EBIT	1,973	1,641	1,885	2,180	2,857	4,027	5,714	7,606	9,748	12,046
Tax rate	15.00%	15.00%	15.00%	15.00%	15.00%	15.00%	15.00%	15.00%	15.00%	15.00%
EBIT*(1-tax rate)	1,677	1,395	1,602	1,853	2,429	3,423	4,857	6,465	8,286	10,239
+ D&A	390	400	410	420	428	437	445	453	460	467
- Change in working capital	111	-56	-113	-148	-186	-214	-211	-90	-95	-102
- Capex	-600	-600	-600	-600	-600	-600	-600	-600	-600	-600
FCFF	1,579	1,140	1,299	1,524	2,071	3,046	4,490	6,227	8,050	10,004
Terminal value										125,760

Terminal growth rate	2.00%
WACC	10.11%
Cost of Equity	13.50%
Cost of Debt	4.50%
Equity Beta	1.00
Risk Free Rate	3.00%
Market Risk Premium	10.50%
Target Debt to Asset ratio	35.00%
Effective Corporate Tax Rate	15.00%

Terminal value (RMB mn)	47,987
Total PV (RMB mn)	67,728
Net debt (RMB mn)	-15,209
Minority interests (RMB mn)	3,278
Equity value (RMB mn)	79,659
Equity value (HK\$ mn)	88,510
# of shares (mn)	2,538
Price per share (HK\$ per share)	34.87

Source: CMBIGM estimates

Figure 5: Sensitivity analysis

		WACC				
		9.11%	9.61%	10.11%	10.61%	11.11%
Terminal growth rate	3.00%	45.27	41.38	38.06	35.21	32.73
	2.50%	42.80	39.34	36.36	33.78	31.52
	2.00%	40.67	37.57	34.87	32.52	30.44
	1.50%	38.83	36.02	33.56	31.39	29.47
	1.00%	37.21	34.65	32.39	30.38	28.60

Source: CMBIGM estimates

Figure 6: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Revenue	9,170	9,168	10,090	10,332	11,040	11,830	-11.2%	-17.0%	-14.7%
Gross profit	7,798	7,614	8,421	9,019	9,544	10,168	-13.5%	-20.2%	-17.2%
Operating profit	2,355	2,015	2,252	3,206	3,236	3,557	-26.5%	-37.7%	-36.7%
Attributable net profit	1,898	1,616	1,815	2,927	3,064	3,199	-35.1%	-47.2%	-43.3%
EPS (RMB)	0.75	0.64	0.72	1.07	1.13	1.19	-30.3%	-43.5%	-39.9%
Gross margin	85.04%	83.05%	83.46%	87.29%	86.45%	85.95%	-2.26ppt	-3.4ppt	-2.49ppt
Operating margin	25.68%	21.98%	22.31%	31.03%	29.31%	30.07%	-5.35ppt	-7.33ppt	-7.75ppt
Net margin	20.70%	17.63%	17.99%	28.33%	27.75%	27.04%	-7.63ppt	-10.12ppt	-9.06ppt

Source: Company data, Bloomberg, CMBIGM estimates

Financial Summary

INCOME STATEMENT	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Revenue	7,816	9,108	17,696	9,170	9,168	10,090
Cost of goods sold	(1,174)	(1,280)	(1,348)	(1,372)	(1,554)	(1,669)
Gross profit	6,642	7,828	16,347	7,798	7,614	8,421
Selling expense	(3,006)	(3,351)	(3,631)	(3,388)	(3,556)	(3,979)
Admin expense	(481)	(502)	(651)	(525)	(536)	(587)
R&D expense	(795)	(1,327)	(1,520)	(1,948)	(1,932)	(2,038)
Others	(139)	(89)	381	419	425	434
Operating profit	2,221	2,560	10,926	2,355	2,015	2,252
Share of (losses)/profits of associates/JV	(30)	349	(102)	0	0	0
Net Interest income/(expense)	(212)	(191)	(76)	(64)	(49)	(34)
Pre-tax profit	1,978	2,718	10,748	2,292	1,966	2,218
Income tax	(392)	(501)	(1,652)	(344)	(295)	(333)
Minority interest	37	127	614	50	55	70
Attributable net profit	1,549	2,090	8,482	1,898	1,616	1,815

BALANCE SHEET	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Current assets	9,193	9,347	22,671	23,131	23,705	24,332
Cash & equivalents	2,611	2,143	12,177	12,970	13,335	13,797
Account receivables	1,095	1,305	1,082	618	618	680
Inventories	778	795	1,048	926	1,037	1,099
Prepayment	1,132	741	811	1,063	1,162	1,202
Financial assets at FVTPL	3,303	3,769	3,858	3,858	3,858	3,858
Other current assets	274	594	3,696	3,696	3,696	3,696
Non-current assets	14,432	14,866	13,580	13,775	13,960	14,135
PP&E	4,692	4,993	4,994	5,224	5,443	5,651
Intangibles	1,554	1,685	1,765	1,749	1,733	1,717
Goodwill	4,199	4,253	4,172	4,172	4,172	4,172
Other non-current assets	3,986	3,935	2,649	2,630	2,612	2,595
Total assets	23,625	24,213	36,250	36,906	37,665	38,468
Current liabilities	3,728	5,464	4,416	3,695	3,348	2,900
Short-term borrowings	2,112	2,244	1,831	1,331	831	331
Account payables	212	180	245	93	105	113
Tax payable	33	50	172	172	172	172
Other current liabilities	1,371	2,990	2,169	2,100	2,241	2,285
Non-current liabilities	3,384	713	1,398	1,398	1,398	1,398
Long-term borrowings	1,463	38	723	723	723	723
Bond payables	1,226	0	0	0	0	0
Deferred income	412	390	374	374	374	374
Other non-current liabilities	283	285	301	301	301	301
Total liabilities	7,111	6,176	5,814	5,093	4,746	4,299
Share capital	0	0	0	0	0	0
Other reserves	10,752	12,942	21,667	22,994	24,045	25,224
Others	3,282	2,494	5,541	5,541	5,541	5,541
Total shareholders equity	14,034	15,436	27,208	28,535	29,586	30,765
Minority interest	2,480	2,600	3,228	3,278	3,333	3,403
Total equity and liabilities	23,625	24,213	36,250	36,906	37,665	38,468

CASH FLOW	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	1,978	2,718	10,748	2,292	1,966	2,218
Depreciation & amortization	351	413	543	390	400	410
Tax paid	(471)	(506)	(1,652)	(344)	(295)	(333)
Change in working capital	(162)	566	103	111	(56)	(113)
Others	386	11	(111)	(240)	(262)	(286)
Net cash from operations	2,083	3,201	9,630	2,209	1,754	1,897
Investing						
Capital expenditure	(704)	(963)	(600)	(600)	(600)	(600)
Others	(641)	(394)	304	318	325	334
Net cash from investing	(1,345)	(1,358)	(296)	(282)	(275)	(266)
Financing						
Dividend paid	(225)	(555)	(571)	(571)	(566)	(635)
Net borrowings	1,188	(1,264)	(500)	(500)	(500)	(500)
Others	(1,316)	(434)	2,182	(64)	(49)	(34)
Net cash from financing	(353)	(2,253)	1,111	(1,135)	(1,114)	(1,169)
Net change in cash						
Cash at the beginning of the year	2,152	2,611	2,143	12,177	12,970	13,335
Exchange difference	75	(59)	0	0	0	0
Cash at the end of the year	2,611	2,143	12,588	12,970	13,335	13,797
GROWTH	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Revenue	13.8%	16.5%	94.3%	(48.2%)	(0.0%)	10.1%
Gross profit	17.1%	17.9%	108.8%	(52.3%)	(2.4%)	10.6%
Operating profit	(8.1%)	15.3%	326.8%	(78.4%)	(14.5%)	11.8%
Net profit	(19.1%)	34.9%	305.8%	(77.6%)	(14.8%)	12.3%
PROFITABILITY	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Gross profit margin	85.0%	86.0%	92.4%	85.0%	83.0%	83.5%
Operating margin	28.4%	28.1%	61.7%	25.7%	22.0%	22.3%
Return on equity (ROE)	11.5%	14.2%	39.8%	6.8%	5.6%	6.0%
GEARING/LIQUIDITY/ACTIVITIES	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
Net debt to equity (x)	(0.0)	(0.1)	(0.5)	(0.5)	(0.5)	(0.6)
Current ratio (x)	2.5	1.7	5.1	6.3	7.1	8.4
Receivable turnover days	56.2	48.1	24.6	24.6	24.6	24.6
Inventory turnover days	231.6	224.3	249.4	246.4	243.4	240.4
Payable turnover days	71.7	55.9	57.4	57.4	57.4	57.4
VALUATION	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Dec						
P/E	26.3	19.3	4.8	22.3	26.2	23.3
P/E (diluted)	26.7	19.7	4.9	22.3	26.2	23.3
P/B	2.5	2.2	1.3	1.3	1.3	1.2
Div yield (%)	1.3	1.3	1.4	1.3	1.3	1.5

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.